Japan Pharmaceuticals & Clinical Research Reservations open Page created Nov 16, 2026

List of Companies with Japan SAKIGAKE Designation

Companies holding Japan's SAKIGAKE (pioneering) designation from MHLW for drugs, medical devices, in vitro diagnostics and regenerative medical products, organised by applicant with product code, intended indication, designation date and approval status — a starting point for Japan partnering and in-licensing.

Fields we plan to include

Company (applicant)
Product name / code
Product type (drug, device, IVD, regenerative)
Intended indication
Designation date
Designation scheme (pilot SAKIGAKE or statutory pioneering)
Approval date and brand name
Status (approved, conditional, rescinded, transferred)
Academic seed origin
Company website

Data Preview

* Free sample rows, unverified and may contain errors. This list isn't for sale yet.
CompanyProductIndicationDesignated
Nobelpharma Co., Ltd.SourceNPC-12G (sirolimus gel)Angiofibroma associated with tuberous sclerosis complex2015-10-27
Nippon Shinyaku Co., Ltd.SourceNS-065/NCNP-01Duchenne muscular dystrophy2015-10-27
OrphanPacific, Inc.SourceBCX7353Management of angioedema attacks in hereditary angioedema2015-10-27
Stella Pharma CorporationSourceSPM-011Recurrent malignant glioma; unresectable locally recurrent or locally advanced head and neck cancer2017-04-21
Nipro CorporationSourceSTR01 (autologous bone marrow mesenchymal stem cells)Neurological symptoms and functional impairment from spinal cord injury2016-02-10

Estimated ~75 entries. If people reserve it, we'll try to compile it (we can't compile every list).

* No charge now. Purchase is optional.

Japan SAKIGAKE and pioneering designations: who holds them and why it matters

SAKIGAKE (Japanese for "forerunner") is the Ministry of Health, Labour and Welfare's expedited pathway for innovative medical products that are developed for Japan first or in parallel with other major markets. It came out of the Strategy of SAKIGAKE announced by MHLW in June 2014 and is run together with the Pharmaceuticals and Medical Devices Agency (PMDA). For a business development team, a designation is a useful signal: it marks a programme that Japanese regulators have already judged to be innovative, aimed at a serious condition, and likely to show prominent efficacy on early data.

Two generations of the scheme

SchemeLegal basisPeriodProduct types
SAKIGAKE designation (pilot)Administrative notificationsDesignations made in FY2015 to FY2020Drugs, medical devices, in vitro diagnostics, regenerative medical products
Pioneering designation (先駆的医薬品等指定)Amended Pharmaceuticals and Medical Devices ActFrom 2021 onwardDrugs, medical devices, regenerative medical products

PMDA keeps seven separate tables, one per scheme and product type, each with the applicant, the intended indication at designation, and any later approval, brand name, transfer or rescission. The tables are maintained as Japanese PDFs dated individually, so building a company-level view means reconciling all seven and translating applicant names consistently.

What a designation gives the developer

  • Prioritised consultation with PMDA, with shorter waiting times for clinical trial and development advice.
  • Pre-application review, letting parts of the dossier be assessed before formal submission.
  • Priority review with a target total review time of around six months, compared with the standard target of about twelve months for new drugs.
  • A dedicated review partner at PMDA who coordinates manufacturing, safety and review functions across the process.

Designation criteria

MHLW looks for four elements together: an innovative mechanism or approach, a serious target disease, prominent efficacy suggested by non-clinical and early clinical data, and an intention to file in Japan first or at the same time as in other regions. The last criterion is what makes the list relevant to market-entry teams: designated programmes are by definition Japan-first or Japan-parallel assets.

What the record shows

  • Many designations reached approval in Japan. Examples in the PMDA tables include Xofluza (baloxavir marboxil, Shionogi) approved in February 2018, Rapalimus Gel (sirolimus, Nobelpharma) in March 2018, and Viltepso (viltolarsen, Nippon Shinyaku) in March 2020.
  • Regenerative products often used conditional, time-limited approval. Stemirac (Nipro) for spinal cord injury and Delytact (G47Δ, Daiichi Sankyo) for malignant glioma were both approved with conditions and a seven-year limit.
  • Academic seeds are common. The device and regenerative tables name the originating university or national centre for many products, such as Sapporo Medical University for STR01 and the National Cancer Center for the NCC Oncopanel system.
  • Designations can be rescinded or transferred. The tables record withdrawals (for example pembrolizumab in gastric cancer in 2017) and transfers between companies, such as the BCX7353 designation passing from OrphanPacific through another company to BioCryst Pharmaceuticals.

How buyers use the designation record

  1. Partnering scans: pick out Japanese mid-size firms and venture companies that hold a designation but have no global partner for ex-Japan rights.
  2. Japan entry benchmarking: compare designation-to-approval times by modality to set realistic timelines for a Japan-first filing.
  3. Investor diligence: check whether a portfolio company's claimed Japan advantage is backed by a formal MHLW designation and whether it is still active.
A designation applies to a specific product and indication. When a company changes the indication or the development plan, the designation can lapse even though the company remains active in the field.

Frequently Asked Questions

Q.What is the difference between SAKIGAKE designation and pioneering designation?

SAKIGAKE designation was the original scheme run under MHLW notifications, with designations made from FY2015 to FY2020. The amended Pharmaceuticals and Medical Devices Act turned it into a statutory pioneering designation for drugs, medical devices and regenerative medical products, with designations from 2021 onward.

Q.Does a SAKIGAKE designation require filing in Japan first?

The criteria require an intention to file in Japan first or at the same time as in other major markets. Designations are aimed at programmes where Japan is not a later follow-on market.

Q.How fast is review under a SAKIGAKE designation?

The target total review time is around six months, compared with roughly twelve months for a standard new drug review, supported by prioritised consultation and pre-application review with PMDA.

Q.Can a SAKIGAKE designation be withdrawn?

Yes. PMDA's tables record rescinded designations, for example when development of the designated indication stops or the plan no longer meets the criteria, as well as transfers of a designation to another company.

Q.Can I buy the list now?

Not yet. Sample rows are free. We try to compile lists that people reserve (we can't compile every list). If we do, we'll email everyone who reserved it a purchase link (buying is optional). If we don't, nothing happens and you're never charged.

Q.What does it cost?

Sample rows are free. A list is $49, paid only if we compile it and you decide to buy. There is no free trial or subscription.